MA61003A1 - Immunocytokine pour activer le récepteur il-10ra humain et son utilisation - Google Patents

Immunocytokine pour activer le récepteur il-10ra humain et son utilisation

Info

Publication number
MA61003A1
MA61003A1 MA61003A MA61003A MA61003A1 MA 61003 A1 MA61003 A1 MA 61003A1 MA 61003 A MA61003 A MA 61003A MA 61003 A MA61003 A MA 61003A MA 61003 A1 MA61003 A1 MA 61003A1
Authority
MA
Morocco
Prior art keywords
immunocytokine
receptor
activating
human
methods
Prior art date
Application number
MA61003A
Other languages
English (en)
Other versions
MA61003B1 (fr
Inventor
Stanislav Rudolfovich Evdokimov
Pavel Andreevich Iakovlev
Valery Vladimirovich Solovyev
Dmitry Valentinovich Morozov
Iana Andreevna Smirnova
Sergei Andreevich Ageev
Vladimir Sergeevich Tsympilov
Aleksey Vladimirovich Kononov
Iuliia Viktorovna Evdokimovskaia
Elena Sergeevna Kolosova
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2020140807A external-priority patent/RU2810750C2/ru
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of MA61003A1 publication Critical patent/MA61003A1/fr
Publication of MA61003B1 publication Critical patent/MA61003B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention relève du domaine de la biotechnologie et de la médecine, et concerne en particulier une immunocytokine pour activer le récepteur il-10ra humain. L'invention concerne en outre des acides nucléiques codant pour ladite immunocytokine, des vecteurs d'expression, des cellules hôtes et leurs procédés de production, des procédés de production de l'immunocytokine, des compositions pharmaceutiques comprenant ladite immunocytokine, des compositions pharmaceutiques comprenant l'immunocytokine ci-dessus et d'autres composés thérapeutiquement actifs, des méthodes de traitement d'une maladie oncologique et des utilisations de l'immunocytokine ou leurs compositions pharmaceutiques pour le traitement d'une maladie oncologique.
MA61003A 2020-12-10 2021-12-10 Immunocytokine pour activer le récepteur il-10ra humain et son utilisation MA61003B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2020140807A RU2810750C2 (ru) 2020-12-10 Иммуноцитокин для активации IL-10Rα рецептора человека и его применение
PCT/RU2021/050432 WO2022124950A1 (fr) 2020-12-10 2021-12-10 Immunocytokine pour activer le récepteur il-10ra humain et son utilisation

Publications (2)

Publication Number Publication Date
MA61003A1 true MA61003A1 (fr) 2023-10-31
MA61003B1 MA61003B1 (fr) 2024-12-31

Family

ID=81973601

Family Applications (1)

Application Number Title Priority Date Filing Date
MA61003A MA61003B1 (fr) 2020-12-10 2021-12-10 Immunocytokine pour activer le récepteur il-10ra humain et son utilisation

Country Status (22)

Country Link
US (1) US20240034764A1 (fr)
EP (1) EP4259644A4 (fr)
JP (1) JP7890293B2 (fr)
KR (1) KR20230118919A (fr)
CN (1) CN117120461A (fr)
AR (1) AR124310A1 (fr)
AU (1) AU2021398529A1 (fr)
CA (1) CA3201656A1 (fr)
CL (1) CL2023001677A1 (fr)
CO (1) CO2023007563A2 (fr)
CR (1) CR20230243A (fr)
EC (1) ECSP23043458A (fr)
IL (1) IL303501A (fr)
JO (1) JOP20230129A1 (fr)
MA (1) MA61003B1 (fr)
MX (1) MX2023006830A (fr)
PE (1) PE20241070A1 (fr)
PY (1) PY21108779A (fr)
TW (1) TW202237631A (fr)
UY (1) UY39562A (fr)
WO (1) WO2022124950A1 (fr)
ZA (1) ZA202306053B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024406222A1 (en) 2023-12-20 2026-06-04 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rβ) and related methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9346872B2 (en) * 2012-08-08 2016-05-24 Roche Glycart Ag Interleukin-10 fusion proteins
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
BR112016016658A2 (pt) * 2014-02-06 2018-01-23 F. Hoffmann-La Roche Ag proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão
JP7356726B2 (ja) 2017-09-25 2023-10-05 ディンフー バイオターゲット カンパニー リミテッド タンパク性ヘテロ二量体及びその使用
CN111315398A (zh) 2017-11-10 2020-06-19 阿尔莫生物科技股份有限公司 白介素-10与免疫检查点途径抑制剂的组合的组合物和使用方法
CN113811549A (zh) * 2019-02-21 2021-12-17 Xencor股份有限公司 非靶向和靶向性il-10 fc融合蛋白
US20220227827A1 (en) 2019-03-25 2022-07-21 Dingfu Biotarget Co., Ltd. Proteinaceous heterodimer and use thereof

Also Published As

Publication number Publication date
KR20230118919A (ko) 2023-08-14
PY21108779A (es) 2022-08-11
CN117120461A (zh) 2023-11-24
EP4259644A4 (fr) 2024-10-16
ZA202306053B (en) 2026-05-27
CO2023007563A2 (es) 2023-07-21
PE20241070A1 (es) 2024-05-13
JP2023553934A (ja) 2023-12-26
UY39562A (es) 2022-05-31
WO2022124950A1 (fr) 2022-06-16
IL303501A (en) 2023-08-01
CA3201656A1 (fr) 2022-06-16
EP4259644A1 (fr) 2023-10-18
ECSP23043458A (es) 2023-07-31
CL2023001677A1 (es) 2024-01-19
CR20230243A (es) 2023-07-13
US20240034764A1 (en) 2024-02-01
MA61003B1 (fr) 2024-12-31
MX2023006830A (es) 2023-07-06
TW202237631A (zh) 2022-10-01
JOP20230129A1 (ar) 2023-06-08
JP7890293B2 (ja) 2026-07-14
AU2021398529A9 (en) 2024-10-24
AU2021398529A1 (en) 2023-06-29
AR124310A1 (es) 2023-03-15

Similar Documents

Publication Publication Date Title
Maekawa et al. Antagonistic effects of IL-17 and D-resolvins on endothelial Del-1 expression through a GSK-3β-C/EBPβ pathway
Kim et al. Bacterial-derived exopolysaccharides enhance antifungal drug tolerance in a cross-kingdom oral biofilm
Tursi et al. Bacterial amyloid curli acts as a carrier for DNA to elicit an autoimmune response via TLR2 and TLR9
Wei et al. Inhibition of Ctsk modulates periodontitis with arthritis via downregulation of TLR9 and autophagy
Zeuner et al. Controversial role of Toll-like receptor 4 in adult stem cells
Irshad et al. Cytokine and matrix metalloproteinase expression in fibroblasts from peri‐implantitis lesions in response to viable P orphyromonas gingivalis
WO2022216787A3 (fr) Nanoparticules lipidiques et leurs méthodes d'utilisation
Deng et al. Prostacyclin-producing human mesenchymal cells target H19 lncRNA to augment endogenous progenitor function in hindlimb ischaemia
Li et al. DNA-based hydrogels with multidrug sequential release for promoting diabetic wound regeneration
Han et al. Effect of human periodontal ligament stem cell-derived extracellular vesicles on macrophage pyroptosis and periodontal inflammatory injury in periodontitis
WO2018230960A3 (fr) Nouvelle souche de bifidobacterium bifidum et polysaccharide dérivé de la souche
MA40955A (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
Balducci et al. The human amniotic fluid stem cell secretome triggers intracellular Ca2+ oscillations, NF‐κB nuclear translocation and tube formation in human endothelial colony‐forming cells
Huang et al. Autophagy-mediated circHIPK2 promotes lipopolysaccharide-induced astrocytic inflammation via SIGMAR1
Wang et al. Porphyromonas gingivalis lipopolysaccharide activates canonical Wnt/β-catenin and p38 MAPK signalling in stem cells from the apical papilla
Rafiee et al. Maprotiline inhibits COX2 and iNOS gene expression in lipopolysaccharide-stimulated U937 macrophages and carrageenan-induced paw edema in rats
Mourad et al. Antisenescence therapy improves function in a human model of cardiac fibrosis-on-a-chip
Li et al. Hypoxia regulates the proliferation and osteogenic differentiation of human periodontal ligament cells under cyclic tensile stress via mitogen‐activated protein kinase pathways
MA61003B1 (fr) Immunocytokine pour activer le récepteur il-10ra humain et son utilisation
Zhang et al. The suppression effect of SCH-79797 on Streptococcus mutans biofilm formation
Zhou et al. Confined mechanical microenvironment regulated antibiotic resistance in 3D biofilm aggregates probed by scanning electrochemical microscopy
Branco‐de‐Almeida et al. Protective effects of desipramine on alveolar bone in experimental periodontitis
Worton et al. Botulinum toxin A-induced muscle paralysis stimulates Hdac4 and differential miRNA expression
Roky et al. Identification of small-molecule inhibitors targeting Porphyromonas gingivalis interspecies adherence and determination of their in vitro and in vivo efficacies
Li et al. A promising platform of nanovesicles as a synergistic strategy for antibacterial and immunomodulation in treating periodontitis